Gland Pharma Share Price
2910.20+0.00 (-0.22%)
+44.27% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
GLANDNSE
Gland Pharma Share Price
2910.20+0.00 (-0.22%)
+44.27% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | 13% | 21% | 14% |
| - | 1% | 10% | 47% |
| - | -6% | 20% | 44% |
| 14% | 11% | 9% | 11% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
GLAND
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,849.9 | ₹447476 Cr | 37 | 12.07 | 62.82 | ₹11479 Cr |
| 9,602 | ₹254764 Cr | 87.1 | 34.04 | 128.41 | ₹2568 Cr |
| 4,928.5 | ₹189423 Cr | 86.85 | 16.72 | 97.06 | ₹2163 Cr |
| 1,180.3 | ₹116658 Cr | 25.85 | 9.42 | 62.53 | ₹5040 Cr |
| 1,399 | ₹111484 Cr | 33.08 | 9.77 | 57.87 | ₹3879 Cr |
| 2,026.2 | ₹109943 Cr | 100.55 | 6.8 | 29.25 | ₹889 Cr |
| 2,500 | ₹101712 Cr | 49.79 | 13.75 | 71.08 | ₹1913 Cr |
| 1,200.4 | ₹101005 Cr | 31.35 | 5.32 | 63.99 | ₹4196 Cr |
| 1,716 | ₹99253 Cr | 26.73 | 17.95 | 96.84 | ₹3505 Cr |
| 2,100.7 | ₹96031 Cr | 17.37 | 30.95 | 154.35 | ₹5333 Cr |
| 2,897.4 | ₹47985 Cr | 42.51 | 19.21 | 94.7 | ₹1027 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — |
| ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹16 Cr | ₹15 Cr |
| ₹46 Cr | ₹5 L | ₹1 Cr | ₹2 Cr | ₹13 Cr | ₹25 Cr | ₹16 Cr |
| ₹10296 Cr | ₹9134 Cr | ₹8706 Cr | ₹7941 Cr | ₹7128 Cr | ₹5861 Cr | ₹3614 Cr |
| ₹10296 Cr | ₹9134 Cr | ₹8706 Cr | ₹7941 Cr | ₹7128 Cr | ₹5861 Cr | ₹3614 Cr |
| ₹10358 Cr | ₹9151 Cr | ₹8724 Cr | ₹7959 Cr | ₹7158 Cr | ₹5903 Cr | ₹3646 Cr |
| ₹70 Cr | ₹78 Cr | ₹107 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| ₹152 Cr | ₹163 Cr | ₹170 Cr | ₹84 Cr | ₹88 Cr | ₹74 Cr | ₹74 Cr |
| ₹65 Cr | ₹71 Cr | ₹75 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr |
| ₹196 Cr | ₹146 Cr | ₹137 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹482 Cr | ₹457 Cr | ₹489 Cr | ₹90 Cr | ₹94 Cr | ₹80 Cr | ₹81 Cr |
| — | — | — | — | — | — | — |
| ₹834 Cr | ₹820 Cr | ₹768 Cr | ₹587 Cr | ₹463 Cr | ₹396 Cr | ₹249 Cr |
| ₹658 Cr | ₹620 Cr | ₹520 Cr | ₹109 Cr | ₹76 Cr | ₹62 Cr | ₹82 Cr |
| ₹117 Cr | ₹125 Cr | ₹111 Cr | ₹32 Cr | ₹43 Cr | ₹54 Cr | ₹28 Cr |
| ₹1608 Cr | ₹1565 Cr | ₹1398 Cr | ₹729 Cr | ₹582 Cr | ₹513 Cr | ₹359 Cr |
| ₹12449 Cr | ₹11173 Cr | ₹10611 Cr | ₹8778 Cr | ₹7834 Cr | ₹6496 Cr | ₹4086 Cr |
| ₹10 Cr | ₹21 Cr | ₹16 Cr | ₹22 Cr | ₹13 Cr | ₹75 Cr | ₹12 Cr |
| ₹243 Cr | ₹269 Cr | ₹320 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr |
| — | — | — | — | — | — | — |
| ₹6785 Cr | ₹5613 Cr | ₹5012 Cr | ₹2295 Cr | ₹2081 Cr | ₹1431 Cr | ₹1348 Cr |
| ₹2292 Cr | ₹1466 Cr | ₹1065 Cr | ₹724 Cr | ₹579 Cr | ₹476 Cr | ₹380 Cr |
| ₹4492 Cr | ₹4147 Cr | ₹3947 Cr | ₹1571 Cr | ₹1502 Cr | ₹954 Cr | ₹968 Cr |
| ₹342 Cr | ₹151 Cr | ₹238 Cr | ₹177 Cr | ₹181 Cr | ₹338 Cr | ₹188 Cr |
| ₹83 Cr | ₹88 Cr | ₹119 Cr | ₹129 Cr | ₹286 Cr | ₹78 Cr | ₹82 Cr |
| ₹4 Cr | ₹4 Cr | ₹662 Cr | ₹0 | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| ₹4922 Cr | ₹4390 Cr | ₹4966 Cr | ₹1877 Cr | ₹1982 Cr | ₹1372 Cr | ₹1240 Cr |
| — | — | — | — | — | — | — |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹155 Cr | ₹0 | ₹0 |
| ₹1744 Cr | ₹1685 Cr | ₹1655 Cr | ₹1945 Cr | ₹1186 Cr | ₹1275 Cr | ₹756 Cr |
| ₹1891 Cr | ₹1517 Cr | ₹1559 Cr | ₹871 Cr | ₹1075 Cr | ₹671 Cr | ₹602 Cr |
| ₹3359 Cr | ₹2556 Cr | ₹1839 Cr | ₹3771 Cr | ₹3093 Cr | ₹3006 Cr | ₹1325 Cr |
| ₹128 Cr | ₹150 Cr | ₹103 Cr | ₹91 Cr | ₹97 Cr | ₹84 Cr | ₹71 Cr |
| ₹404 Cr | ₹875 Cr | ₹489 Cr | ₹222 Cr | ₹247 Cr | ₹88 Cr | ₹92 Cr |
| ₹7527 Cr | ₹6783 Cr | ₹5645 Cr | ₹6901 Cr | ₹5852 Cr | ₹5124 Cr | ₹2846 Cr |
| ₹5918 Cr | ₹5218 Cr | ₹4247 Cr | ₹6172 Cr | ₹5270 Cr | ₹4611 Cr | ₹2487 Cr |
| ₹12449 Cr | ₹11173 Cr | ₹10611 Cr | ₹8778 Cr | ₹7834 Cr | ₹6496 Cr | ₹4086 Cr |
| ₹626 | ₹555 | ₹530 | ₹483 | ₹435 | ₹359 | ₹234 |
| ₹626 | ₹555 | ₹530 | ₹483 | ₹435 | ₹359 | ₹234 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
| ₹1465 Cr | ₹1063 Cr | ₹1133 Cr | ₹1055 Cr | ₹1619 Cr | ₹1335 Cr | ₹993 Cr |
| ₹277 Cr | ₹212 Cr | ₹224 Cr | ₹38 Cr | -₹28 Cr | ₹17 Cr | ₹32 Cr |
| -₹254 Cr | -₹6 Cr | -₹53 Cr | -₹418 Cr | -₹393 Cr | -₹436 Cr | -₹80 Cr |
| ₹1487 Cr | ₹1269 Cr | ₹1303 Cr | ₹675 Cr | ₹1197 Cr | ₹916 Cr | ₹945 Cr |
| ₹1031 Cr | ₹915 Cr | ₹997 Cr | ₹364 Cr | ₹791 Cr | ₹605 Cr | ₹701 Cr |
| ₹138 Cr | ₹1705 Cr | -₹1757 Cr | ₹1208 Cr | -₹1003 Cr | -₹1524 Cr | -₹766 Cr |
| -₹417 Cr | -₹433 Cr | -₹799 Cr | ₹15 Cr | ₹35 Cr | ₹1238 Cr | -₹7 Cr |
| ₹752 Cr | ₹2186 Cr | -₹1560 Cr | ₹1587 Cr | -₹177 Cr | ₹319 Cr | -₹72 Cr |
| ₹2556 Cr | ₹357 Cr | ₹1909 Cr | ₹319 Cr | ₹492 Cr | ₹169 Cr | ₹236 Cr |
| ₹51 Cr | ₹13 Cr | ₹8 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹5 Cr |
| ₹3359 Cr | ₹2556 Cr | ₹357 Cr | ₹1909 Cr | ₹319 Cr | ₹492 Cr | ₹169 Cr |
Fundamental Ratios
Consolidated
Standalone
Gland Pharma Share Price
2910.20+0.00 (-0.22%)
+44.27% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 2 out of 9 oscillators
RSI
54.21Neutral
STOCH %K
47.20Neutral
MACD Level(12,26)
43.02Buy
Ultimate Oscillator
48.15Sell
Aroon Oscillator
66.00Buy
BOP
-0.06Sell
CCI
-3.93Neutral
Williams %R
-52.80Neutral
Momentum
41.80Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 5
Bearish signals: 4 out of 9 moving averages
EMA 9
2919.17Sell
SMA 9
2914.22Sell
EMA 21
2893.06Buy
SMA 21
2911.74Sell
EMA 50
2757.36Buy
SMA 50
2750.71Buy
EMA 200
2270.90Buy
SMA 200
2112.61Buy
WMA 20
2921.98Sell
Pivot
Pivot
Classic
Resistance 5
3201.93
Resistance 4
3133.53
Resistance 3
3065.13
Resistance 2
2996.73
Resistance 1
2956.67
Pivot
2928.33
Support 1
2888.27
Support 2
2859.93
Support 3
2791.53
Support 4
2723.13
Support 5
2654.73
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Gland Pharma Share Price
2910.20+0.00 (-0.22%)
+44.27% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 51.77% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% |
| 8.74% | 7.29% | 7.58% | 7.90% | 7.39% | 6.90% |
| 2.21% | 1.58% | 1.57% | 2.44% | 2.19% | 2.11% |
| 28.23% | 31.78% | 31.42% | 30.19% | 30.67% | 31.16% |
| 9.05% | 7.52% | 7.60% | 7.64% | 7.92% | 8.00% |
Bulk & block deals
Name
Bofa Securities Europe Sa
North Rock Sg Vcc
Kotak Mahindra Mutual Fund
Axis Mutual Fund
Icici Prudential Mutual Fund
Fosun Pharma Industrial Pte. Ltd.
Fosun Pharma Industrial Pte. Ltd.
Kotak Mahindra Mutual Fund
Axis Mutual Fund
Icici Prudential Mutual Fund
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 17 Sep 2026 | Purchase | 42.40 Cr | ₹2,826.60 | 1.50 L | Block | 0.090903 | NSE |
| 17 Sep 2026 | Sell | 42.40 Cr | ₹2,826.60 | 1.50 L | Block | 0.090903 | NSE |
| 04 Sep 2026 | Purchase | 789.47 Cr | ₹2,826.60 | 27.93 L | Bulk | 1.692615 | BSE |
| 04 Sep 2026 | Purchase | 383.57 Cr | ₹2,826.60 | 13.57 L | Bulk | 0.82237 | BSE |
| 04 Sep 2026 | Purchase | 293.68 Cr | ₹2,826.60 | 10.39 L | Bulk | 0.629655 | BSE |
| 04 Sep 2026 | Sell | 2,150.36 Cr | ₹2,827.38 | 76.06 L | Bulk | 4.609089 | BSE |
| 04 Sep 2026 | Sell | 649.29 Cr | ₹2,833.45 | 22.91 L | Bulk | 1.388696 | BSE |
| 04 Sep 2026 | Purchase | 789.47 Cr | ₹2,826.60 | 27.93 L | Block | 1.692615 | BSE |
| 04 Sep 2026 | Purchase | 383.57 Cr | ₹2,826.60 | 13.57 L | Block | 0.82237 | BSE |
| 04 Sep 2026 | Purchase | 293.68 Cr | ₹2,826.60 | 10.39 L | Block | 0.629655 | BSE |
Insider trading & SAST
Client name
Mirae Asset Mutual Fund
Jayatheerth Advani
K Raghuramachandra Rao
K Raghuramachandra Rao
Sreenivasa Rao Suragam
Jayatheerth Advani
Sreenivasa Rao Suragam
Jayatheerth Advani
Jayatheerth Advani
Jayatheerth Advani
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 03 Aug 2026 | Other | Disposal | 0.18 | 4.98 | 0 | — | 3.01 L | 13 Jul 2026 | Market | 82,10,838 | SAST | 29(2) | — |
| 04 Jun 2026 | Designated Person | Disposal | 0.000606 | 0 | 23.55 L | ₹2,355 | 1 K | 01 Jun 2026 | Market Sale | 1,082 | Insider Trading | — | Equity Shares |
| 28 May 2026 | Designated Person | Disposal | 0.000607 | 0 | 23.20 L | ₹2,319.70 | 1 K | 27 May 2026 | Market Sale | 44 | Insider Trading | — | Equity Shares |
| 28 May 2026 | Designated Person | Disposal | 0.000607 | 0 | 23.46 L | ₹2,345.90 | 1 K | 25 May 2026 | Market Sale | 1,044 | Insider Trading | — | Equity Shares |
| 25 May 2026 | Designated Person | Disposal | 0.000303 | 0 | 11.50 L | ₹2,300 | 500 | 21 May 2026 | Market Sale | 1,350 | Insider Trading | — | Equity Shares |
| 25 May 2026 | Designated Person | Disposal | 0.000303 | 0 | 11.78 L | ₹2,355 | 500 | 21 May 2026 | Market Sale | 2,082 | Insider Trading | — | Equity Shares |
| 21 May 2026 | Designated Person | Disposal | 0.000607 | 0 | 21.70 L | ₹2,170 | 1 K | 18 May 2026 | Market Sale | 1,850 | Insider Trading | — | Equity Shares |
| 21 May 2026 | Designated Person | Disposal | 0.00021 | 0 | 7.74 L | ₹2,238 | 346 | 19 May 2026 | Market Sale | 3,582 | Insider Trading | — | Equity Shares |
| 21 May 2026 | Designated Person | Disposal | 0.000607 | 0 | 22.35 L | ₹2,235 | 1 K | 19 May 2026 | Market Sale | 2,582 | Insider Trading | — | Equity Shares |
| 11 Feb 2026 | Designated Person | Disposal | 0.000061 | 0 | 1.89 L | ₹1,888 | 100 | 09 Feb 2026 | Market Sale | 3,928 | Insider Trading | — | Equity Shares |
Gland Pharma Share Price
2910.20+0.00 (-0.22%)
+44.27% past 1 Year
Gland Pharma Limited is focused on meeting diverse injectables needs with a stable supply of affordable and high quality products. It has established a portfolio of injectable products across various
Corporate Actions
Date
Type
Details
Company details
Gland Pharma Share Price
2910.20+0.00 (-0.22%)
+44.27% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Gland Pharma Share Price
2910.20+0.00 (-0.22%)
+44.27% past 1 Year
News
Gland Pharma to hold analyst and investor meetings on September 11
Equity
GLAND
Gland Pharma sees Rs 2,178 crore block trade in pre open session
Equity
GLAND
Gland Pharma faces potential 5 percent promoter stake sale via block deal
Equity
GLAND
Gland Pharma gets USFDA clearance at VSEZ sterile oncology facility inspection
Equity
GLAND
Gland Pharma schedules investor and analyst meetings in early September 2026
Equity
GLAND
Goldman Sachs maintains sell on Gland Pharma, cites expensive valuation
Equity
GLAND
Jefferies upgrades Gland Pharma to Buy after Q1 FY27 beat
Equity
GLAND
Gland Pharma posts higher Q1 EBITDA and margin on yearly basis
Equity
GLAND
Gland Pharma Q1 revenue rises to Rs 1,800 crores from Rs 1,500 crores
Equity
GLAND
Gland Pharma reports higher first quarter net profit on yearly basis
Equity
GLAND
Gland Pharma forms CDMO partnership for sterile injectable production
Equity
GLAND
Gland Pharma partners Neuland Laboratories to expand sterile API capabilities
Equity
GLAND
Gland Pharma gains USFDA approval, launches generic Bridion injection in US
Equity
GLAND
Gland Pharma block trade worth Rs 51.59 crores executed on NSE
Equity
GLAND
Gland Pharma sees Rs 25.01 crores NSE block trade at Rs 2,489.60
Equity
GLAND
Gland Pharma sees Rs 38.88 crores NSE block trade at premium price level
Equity
GLAND
Large NSE block trade executed in Gland Pharma shares at set price level
Equity
GLAND
Gland Pharma informs about allotment of equity shares
Equity
GLAND
Gland Pharma sees Rs 22.91 Crores NSE block trade
Equity
GLAND
Gland Pharma sees Rs 40.07 crore NSE block trade in 172,720 shares
Equity
GLAND

